Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2025-2034³â)
Antiviral Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034
»óǰÄÚµå : 1699340
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 135 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 7,017,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,753,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 12,081,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀåÀº 2024³â¿¡ 606¾ï ´Þ·¯¸¦ ±â·ÏÇßÀ¸¸ç, 2025³âºÎÅÍ 2034³â¿¡ °ÉÃÄ CAGR 3.6%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

HIV/AIDS, BÇü °£¿°, CÇü °£¿°, ÀÎÇ÷翣ÀÚ µîÀÇ ¹ÙÀÌ·¯½º °¨¿° Áõ·Ê Áõ°¡°¡ Ç×¹ÙÀÌ·¯½ºÁ¦ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

Antiviral Drugs Market-IMG1

Ç×¹ÙÀÌ·¯½ºÁ¦´Â ¹ÙÀÌ·¯½º º¹Á¦¸¦ ¾ïÁ¦Çϰí HIV/AIDS, °£¿°, ÀÎÇ÷翣ÀÚ µîÀÇ °¨¿°Áõ Ä¡·á¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾ïÁ¦Á¦´Â Ç×·¹Æ®·Î¹ÙÀÌ·¯½º ¿ä¹ý¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖÀ¸¸ç, ´ºÅ¬·¹¿À½Ãµå°è ¹× ºñ´ºÅ¬·¹¿À½Ãµå°è ¿ªÀü»çÈ¿¼Ò ¾ïÁ¦Á¦°¡ ±× º¸±ÞÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
½ÃÀÛ ±Ý¾× 606¾ï ´Þ·¯
¿¹Ãø ±Ý¾× 854¾ï ´Þ·¯
CAGR 3.6%

ÀûÀÀÁõº°·Î´Â HIV/AIDS ºÐ¾ß°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, 2034³â¿¡´Â 412¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

ºê·£µå Ç×¹ÙÀÌ·¯½ºÁ¦´Â È¿´É°ú ¾ÈÀü¼ºÀ» º¸ÀåÇÏ´Â ¾ö°ÝÇÑ ÀÓ»ó½ÃÇè¿¡ ÈûÀÔ¾î 2024³â¿¡´Â ½ÃÀåÀÇ 71.9%¸¦ Â÷ÁöÇß½À´Ï´Ù.

2024³â¿¡´Â °æ±¸ Ç×¹ÙÀÌ·¯½ºÁ¦°¡ ¼±µµÇß°í CAGR 3.7%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿¬·ÉÃþº°·Î´Â 2024³â¿¡ 269¾ï ´Þ·¯·Î Æò°¡µÈ ³ë³â ºÎ¹®ÀÌ 2032³â¿¡´Â 375¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º´¿ø ¾à±¹Àº 2024³â¿¡ ½ÃÀå Á¡À¯À²ÀÇ 46.7%¸¦ Â÷ÁöÇß°í CAGR 3.3%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹Ì±¹ÀÇ Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀåÀº 2023³â 219¾ï ´Þ·¯, 2022³â 215¾ï ´Þ·¯¿¡¼­ 2024³â¿¡´Â 222¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå Ã߰衤¿¹Ãø : ¾àÁ¦ Ŭ·¡½ºº°(2021-2034³â)

Á¦6Àå ½ÃÀå Ã߰衤¿¹Ãø : ÀûÀÀÁõº°(2021-2034³â)

Á¦7Àå ½ÃÀå Ã߰衤¿¹Ãø : À¯Çüº°(2021-2034³â)

Á¦8Àå ½ÃÀå Ã߰衤¿¹Ãø : Åõ¿© °æ·Îº°(2021-2034³â)

Á¦9Àå ½ÃÀå Ã߰衤¿¹Ãø : ¿¬·ÉÃþº°(2021-2034³â)

Á¦10Àå ½ÃÀå Ã߰衤¿¹Ãø : À¯Åë ä³Îº°(2021-2034³â)

Á¦11Àå ½ÃÀå ¿¹Ãø : Áö¿ªº° ½ÃÀå Ã߰衤¿¹Ãø : Áö¿ªº°(2021-2034³â)

Á¦12Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Antiviral Drugs Market, estimated at USD 60.6 billion in 2024, is set to grow at a CAGR of 3.6% from 2025 to 2034. Increasing cases of viral infections, including HIV/AIDS, hepatitis B and C, and influenza, are driving demand for antiviral medications. Greater awareness, combined with government funding for drug approvals and clinical research, is fostering market growth. Companies are expanding manufacturing capacities to cater to a rising patient base, contributing to increased market penetration.

Antiviral Drugs Market - IMG1

Antiviral drugs inhibit viral replication, playing a crucial role in treating infections such as HIV/AIDS, hepatitis, and influenza. The market is segmented by drug class, with reverse transcriptase inhibitors holding 29.9% of the share at USD 18.1 billion in 2024. These inhibitors are key in antiretroviral therapy, with nucleoside and non-nucleoside reverse transcriptase inhibitors driving their widespread use. Government-backed HIV treatment programs and their cost-effectiveness enhance adoption.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$60.6 Billion
Forecast Value$85.4 Billion
CAGR3.6%

By indication, the HIV/AIDS segment dominates the market and is expected to reach USD 41.2 billion by 2034. A rising number of infections, along with antiretroviral therapy's long-term necessity, is fueling segment growth. Regulatory bodies are streamlining drug development, further boosting expansion.

Branded antiviral drugs accounted for 71.9% of the market in 2024, supported by rigorous clinical trials ensuring efficacy and safety. Branded drugs remain preferred for treating chronic infections due to better therapeutic outcomes. Pharmaceutical companies continue to enhance accessibility, increasing market adoption.

Oral antiviral drugs led in 2024 and are projected to grow at a 3.7% CAGR. Their ease of administration and non-invasive nature make them a preferred choice for long-term treatment. Advances in oral drug formulations are improving patient adherence and treatment effectiveness, further strengthening demand.

By age group, the geriatric segment, valued at USD 26.9 billion in 2024, is expected to reach USD 37.5 billion by 2032. An aging global population with a higher susceptibility to viral infections is driving demand. Increased use of antiviral medications and vaccines among older adults is supporting market expansion.

Hospital pharmacies captured 46.7% of the market share in 2024 and are anticipated to grow at a 3.3% CAGR. Hospitals remain the primary treatment centers for severe viral infections, ensuring easy drug accessibility. The availability of diverse antiviral formulations and the need for hospitalization in critical cases are reinforcing segment dominance.

The U.S. antiviral drugs market stood at USD 22.2 billion in 2024, up from USD 21.9 billion in 2023 and USD 21.5 billion in 2022. Growing government initiatives and rising infection rates are driving demand. Policies focused on eliminating viral diseases and intensifying prevention efforts are further strengthening market growth.

Table of Contents

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2024

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2034 ($ Mn)

Chapter 7 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

Chapter 9 Market Estimates and Forecast, By Age Group, 2021 – 2034 ($ Mn)

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

Chapter 11 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

Chapter 12 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â